

Final Testimonial

Mr. Christopher Weingarten, born on November 20, 1998, joined the Global Drug Development (GDD) / Technical Research & Development (TRD) / Pharmaceutical Development Unit Oral Team Early Phase department of Novartis Pharma AG as **Pharm Development Intern** on November 1, 2022.

In this position, Mr. Weingarten worked as a master's student in a team focusing on the development of solid oral dosage forms for early-phase clinical trials. His main responsibility was to establish an investigational method to assess the risk of salt disproportionation of a drug substance when formulated in a drug product. He quickly developed his proficiency and confidence in the assigned tasks. When conducting the scientific experiments, he showed great planning and time management skills. He demonstrated intrinsic interest and openness to feedback provided from different angles on various topics and acted quickly upon that. Furthermore, he easily connected with colleagues within the team and with colleagues from other teams, which allowed him to improve the quality of his work and execute the project smoothly.

His main duties essentially included:

- Plan, perform and interpret scientific experiments
- Conduct literature research
- Characterize pharmaceutical products
- Organize and plan the analysis of the obtained product
- Communicate scientific findings to supervisors and to the team

Alongside his outstanding general knowledge, Mr. Weingarten also possesses comprehensive specialist skills that enabled him to competently react to changes. His expertise made it possible for him to handle the extensive workload in a short period of time. Thanks to his skills, he independently and successfully implemented demanding tasks. In addition, he was able to analyze and solve new problems very well. He fulfilled our requirements in every respect, and we were most satisfied with his achievement of objectives.

Being an exceptionally dependable individual, Mr. Weingarten worked in an extremely careful and conscientious manner. His level of dedication and flexibility as well as his sense of responsibility and initiative impressed us. Furthermore, he represented our interests with energy and great personal commitment. Even under high pressure, he was able to master his field of work and to carry out all jobs speedily and sensibly. When confronted with new tasks, he quickly recognized the essential points and maintained a clear overview.

Attaching very great importance to the different ideas and approaches of his colleagues, Mr. Weingarten was invariably capable of implementing these suggestions in a targeted and constructive way. He has a very pleasant manner and showed discretion while maintaining a critical approach appropriate in all circumstances.

U NOVARTIS | Reimagining Medicine

Mr. Weingarten leaves us due to the expiration of the temporary employment on April 30, 2023. We would like to take this opportunity to thank him for his successful work. We wish him all the best for his personal and professional future.

Basel, December 06, 2023

Novartis Pharma AG

DocuSigned by:

Hans de Waard

CFA9E653D92F4A3.

Director Pharmaceutical Development Unit Oral EP

—DocuSigned by: Aparna Awasthi

Aparna Awasthi H2R Services Expert